Table 3.
Characteristics of patients rechallenged with HDMTX following glucarpidase administration.
| HDMTX course immediately following glucarpidase | All other HDMTX courses for the same patients | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of patients rechallenged |
Time to MTX rechallenge (days) a [median (range)] |
% of full HDMTX dosage administered at rechallenge [median (range)] |
HDMTX Dosage (g/m2) [median (range)] |
Max Scr (mg/dL) [median (range)] |
SCr % increase from baseline [median (range)] |
Time to complete MTX excretion (hrs) [median (range)] |
Total number of courses |
HDMTX Dosage (g/m2) [median (range)] |
Max Scr (mg/dL) [median (range)] |
SCr % increase from baseline [median (range)] |
Time to complete MTX excretion (hrs) [median (range)] |
|
| All Patients (n = 20) |
13 | 28 (18 – 70) |
67 (50 – 100) |
2.486 (1.6 – 12) |
0.8 (0.4 – 1.6) |
25 (0 – 128.6) |
90 (66 – 268) |
26 | 8.5 (2 – 12) |
0.6 (0.4 – 0.9) |
22.5 (0 – 50) |
72 (42 – 116) |
| Osteosarcoma (n = 6) |
4 | 43 (20 – 70) |
67 (50 – 100) |
8 (6 – 12) |
0.8 (0.5 – 1.6) |
42.5 (14.3 – 128.6) |
96 (72 – 268) |
13 | 12 (12 – 12) |
0.6 (0.5 – 0.9) |
25 (0 – 50) |
72 (72 – 116) |
| ALL (n = 10) |
7 | 27 (18 – 32) |
67 (50 – 100) |
2.02 (1.6 – 2.714) |
0.8 (0.5 – 0.9) |
25 (0 – 100) |
90 (66 – 114) |
10 | 3.153 (2 – 5) |
0.6 (0.4 – 0.9) |
16.3 (0 – 33.3) |
66 (42 – 92) |
| Other (n = 4) |
2 | 26 (23 – 29) |
80 (60 – 100) |
2.243 (2 – 2.486) |
0.8 (0.4 – 1.1) |
28.6 (0 – 57.1) |
78 (66 – 90) |
3 | 3.1 (3 – 4.5) |
0.4 (0.4 – 0.8) |
33.3 (14.3 – 33.3) |
42 (42 – 66) |
HDMTX, high-dose methotrexate; g, grams; SCr, serum creatinine; MTX, methotrexate; mg, milligram; dL, deciliter; hrs, hours; ALL, acute lymphoblastic leukemia
a
The time to methotrexate rechallenge was the time elapsed between the start of the HDMTX course in which glucarpidase was administered and the start of the next HDMTX infusion.